Virus Or Bacteriophage, Except For Viral Vector Or Bacteriophage Vector; Composition Thereof; Preparation Or Purification Thereof; Production Of Viral Subunits; Media For Propagating Patents (Class 435/235.1)
  • Patent number: 10328109
    Abstract: Described herein is an adenovirus comprising an AB-loop comprising a targeting motif and methods of making and using the adenovirus. The targeting motif of the adenovirus can selectively bind to a tumor cell. The targeting motif of the adenovirus can selectively bind to cell markers and/or cell surface antigens including, for example, CD 133.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: June 25, 2019
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventor: Masato Yamamoto
  • Patent number: 10322172
    Abstract: A live, attenuated HIV vaccine is provided, and methods of making a attenuated HIV vaccine are provided.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: June 18, 2019
    Assignee: NUtech Ventures
    Inventors: Jiantao Guo, Qingsheng Li, Wei Niu, Yue Li, Nanxi Wang
  • Patent number: 10316334
    Abstract: CMV vectors comprising a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), and an active UL128 protein (or an ortholog thereof) but lacking an active UL130 protein (or an ortholog thereof) are provided. CMV vectors comprising a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), and an active UL130 protein (or an ortholog thereof) but lacking an active UL128 protein are also provided. In addition, methods of using CMV vectors to generate an immune response characterized as having at least 10% of the CD8+ T cells directed against epitopes presented by MHC Class II are provided.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: June 11, 2019
    Assignee: Oregon Health & Science University
    Inventors: Louis Picker, Scott Hansen, Klaus Frueh, Daniel Malouli
  • Patent number: 10309969
    Abstract: The present invention relates to a method for constructing an Fv library based on a combination of proteins, a method of screening a desired antibody using the constructed Fv library, an Fv antibody screened by the screening method, and an Fv library constructed by the Fv library construction method. The Fv library of the present invention is based on a combination of proteins so that members thereof can be individually analyzed for their function. Moreover, the Fv library enables a desired Fv antibody to be screened without needing a target antigen preparation. In addition, the protein combination based Fv library makes it possible to significantly reduce the number of protein purification processes to thereby reduce costs and time, compared to conventional DNA-based libraries.
    Type: Grant
    Filed: January 24, 2014
    Date of Patent: June 4, 2019
    Assignee: AbTLAS CO., LTD.
    Inventors: Byeong Doo Song, Jee Sun Yun, Song Yi Lee, Hye In Kim, Hyo Jung Choi, Jong Rip Choi
  • Patent number: 10301360
    Abstract: Provided herein are methods of selective screening. In addition, various targeting proteins and sequences, as well as methods of their use, are also provided.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: May 28, 2019
    Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Benjamin E. Deverman, Paul H. Patterson, Viviana Gradinaru
  • Patent number: 10272032
    Abstract: This disclosure provides pharmaceutical adenovirus formulations, in particular, liquid pharmaceutical formulations comprising adenoviruses.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: April 30, 2019
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventor: Janik Adriaansen
  • Patent number: 10267799
    Abstract: The invention relates to isolated peptides and chimeric polypeptides derived from Saposin A that have anti-angiogenic activity. These peptides are small, consisting essentially of at least 10 consecutive amino acid residues from the 31st-50th amino acid residue of Saposin A. The invention also relates to the use of these isolated peptides and chimeric polypeptides in compositions for the treatment, prevention, and inhibition of angiogenesis-related diseases and disorders such as cancer and cancer metastasis.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: April 23, 2019
    Assignee: Children's Medical Center Corporation
    Inventor: Randolph Watnick
  • Patent number: 10253072
    Abstract: The present invention is intended to provide an egg drop syndrome (EDS) vaccine that is capable of effectively preventing EDS and can be stably supplied. The EDS vaccine provided to this end contains as an active ingredient fused protein in which a polypeptide having a coiled-coil forming unit is bound to the knob region in the fiber protein of EDS virus (EDSV).
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: April 9, 2019
    Assignee: KM Biologics Co., Ltd.
    Inventors: Kenichi Yamazaki, Kiyohiko Andoh, Ryuichi Sakamoto, Kiyotaka Suenaga, Takeshi Arakawa, Hirotaka Uefuji, Tetsuya Harakuni, Takeshi Miyata
  • Patent number: 10208292
    Abstract: Methods and compositions for increasing the production of recombinant proteins by introducing ICP0 to cells capable of producing a recombinant protein are encompassed. In one method, the recombinant protein is a protein that is required for the replication of a replication defective virus, wherein the recombinant protein is provided to the replication defective virus in trans.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: February 19, 2019
    Assignee: Sanofi Pasteur Biologics, LLC
    Inventors: Simon Delagrave, CharChang Lai
  • Patent number: 10208304
    Abstract: Described herein is a method that generally includes infecting a host cell with a rescue adenovirus, wherein the rescue adenovirus genome comprises a loxP site and encodes at least one marker, and wherein the host cell comprises a library of polynucleotides that complement the adenovirus genome marker and encode a detectable polypeptide; incubating the infected host cell under conditions effective to permit recombination between the adenovirus genome and one or more of the library polynucleotides and the production of recombinant adenovirus particles comprising at least on detectable polypeptide; and detecting the at least one detectable polypeptide. Also described are adenovirus libraries constructed using such a method.
    Type: Grant
    Filed: April 16, 2012
    Date of Patent: February 19, 2019
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Masato Yamamoto, Yoshiaki Miura
  • Patent number: 10202423
    Abstract: A method of producing a picornavirus-like particle (PVLP) in a plant is provided. The method comprises introducing a first nucleic acid and a second nucleic acid into the plant, portion of the plant, or a plant cell. The first nucleic acid comprising a first regulatory region active in the plant operatively linked to a nucleotide sequence encoding a polyprotein. The second nucleic acid comprises a second regulatory region active in the plant and operatively linked to a nucleotide sequence encoding one or more protease. The plant, portion of the plant, or plant cell is incubated under conditions that permit the expression of the nucleic acids, thereby producing the PVLP. A PVLP comprising the polyprotein is also provided.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: February 12, 2019
    Assignee: Medicago Inc. of Quebec, Canada
    Inventors: Marc-Andre D'Aoust, Pierre-Olivier Lavoie, Manon Couture, Lucie Poulin, Louis-Philippe Vezina
  • Patent number: 10195272
    Abstract: A chimeric antigen receptor (CAR) contains a human Fc?RI? extracellular domain or a mutant Fc?RI? extracellular domain that has a reduced binding affinity for human IgE compared to wild type human Fc?RI? extracellular domain. The CAR further contains an intracellular signaling domain comprising at least one immunoreceptor-based activation motif (ITAM). The CAR may further comprise a costimulatory signaling domain, such as an intracellular domain of at least one of the costimulatory molecules 4-1BB, CD27, CD28, CD134 or ICOS. T cells transduced with vectors encoding the CAR are used in CAR-based adoptive T-cell therapy for targeting IgE-expressing B cells and treating IgE-mediated allergic diseases.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: February 5, 2019
    Assignee: The Nemours Foundation
    Inventor: Zhengyu Ma
  • Patent number: 10190098
    Abstract: The present invention relates to production of proteins in insect cells whereby repeated coding sequences are used in baculoviral vectors. In particular the invention relates to the production of parvoviral vectors that may be used in gene therapy and to improvements in expression of the viral rep proteins that increase the productivity of parvoviral vectors.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: January 29, 2019
    Assignee: UniQure IP B.V.
    Inventors: Andrew Christian Bakker, Wilhelmus Theodorus Johannes Maria C Hermens
  • Patent number: 10188723
    Abstract: The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: January 29, 2019
    Assignee: NOVAVAX, INC.
    Inventors: Gale Smith, Rick Bright, Peter M. Pushko, Jinyou Zhang, Kutub Mahmood
  • Patent number: 10179112
    Abstract: The invention provides novel methods, materials and systems that can be used to generate viral vectors having altered tissue and cell targeting abilities. In illustrative embodiments of the invention, the specificity of lentiviral vectors was modulated by a thin polymer shell that synthesized and coupled to the viral envelope in situ. The polymer shell can confers such vectors with new targeting ability via agents such as cyclic RGD (cRGD) peptides that are coupled to the polymer shell. These polymer encapsulated viral vectors exhibit a number of highly desirable characteristics including a higher thermal stability, resistance to serum inactivation in vivo, and an ability to infect dividing and non-dividing cells with high efficiencies.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: January 15, 2019
    Assignee: The Regents of the University of California
    Inventors: Yunfeng Lu, Ming Yan, Irvin S. Y. Chen, Min Liang
  • Patent number: 10160979
    Abstract: The present invention can induce stronger cellular immunity to hepatitis C and provide a treatment means and a prevention means that are effective in completely eliminating the hepatitis C virus (HCV). Provided is a pharmaceutical composition for the treatment and/or prevention of hepatitis C, said composition comprising a recombinant vaccinia virus (a) and a recombinant vector (b) and characterized in that after one of the recombinant vaccinia virus (a) and the recombinant vector (b) is administered for initial immunity, the other is administered for additional immunity. The recombinant vaccinia virus (a) contains an expression promoter and all or a portion of the cDNA of the HCV genome. The recombinant vector (b) contains an expression promoter and all or a portion of the cDNA of the HCV (where the cDNA contained in the recombinant vector (b) has a different base sequence than that included in the recombinant vaccinia virus (a)).
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: December 25, 2018
    Assignees: Tokyo Metropolitan Institute of Medical Science, National Institutes of Biomedical Innovation, Health and Nutrition, KM Biologics Co., Ltd.
    Inventors: Michinori Kohara, Yasuhiro Yasutomi, Yumiko Shiogama
  • Patent number: 10150805
    Abstract: The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor ?/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus).
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: December 11, 2018
    Assignee: Altor Bioscience, LLC
    Inventors: Hing C. Wong, Peter Rhode, Bai Liu, Xiaoyun Zhu, Kai-Ping Han
  • Patent number: 10125402
    Abstract: Methods for the measuring cell-free nucleic acids and/or virus particles from dried blood spots are described. The methods can include the steps of rehydrating a dried blood sample, optionally fixing cells present in the rehydrated dried blood sample, eluting cell-free virus particles from the rehydrated dried blood sample, separating the cell-free viruses from any cell debris that may be present in the rehydrated dried blood sample by way of a filter, and measuring cell-free virus particles by a viral particle quantification technique.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: November 13, 2018
    Assignee: ROCHE MOLECULAR SYSTEMS, INC.
    Inventors: Paul Baum, Megan M. Crask, Xiaoning Wu
  • Patent number: 10118135
    Abstract: The present invention provides a virus hybrid separation film and a method for manufacturing the same, capable of improving selective permeability using nano-pores of a virus. The separation film according to the present invention comprises: a porous support layer; and an active layer, disposed on the porous support layer, for having a target material selectively permeate thereinto, wherein the active layer comprises: a plurality of virus assemblies having pores; and an impermeable supporter. The impermeable supporter is positioned between the plurality of virus assemblies and supports the virus assemblies.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: November 6, 2018
    Assignee: Korea Institute of Energy Research
    Inventors: Chul-Ho Park, Namjo Jeong, Harim Bae, Jiyeon Choi, Seung Cheol Yang
  • Patent number: 10117896
    Abstract: The present invention provides compositions and methods for inducing a CAR mediated trans-signal in a T cell. The trans-signaling CAR T cells comprise a first CAR having a first signaling module and a second CAR having a distinct second signaling module. The present invention also provides cells comprising a plurality of types of CARs, wherein the plurality of types of CARs participate in trans-signaling to induce T cell activation.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: November 6, 2018
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Daniel J. Powell, Jr., Carl H. June
  • Patent number: 10086073
    Abstract: A method for identifying a molecule that binds an irradiated tumor in a subject and molecules identified thereby. In some embodiments, the method includes the steps of (a) exposing a tumor to ionizing radiation; (b) administering to a subject a library of diverse molecules; and (c) isolating from the tumor one or more molecules of the library of diverse molecules, whereby a molecule that binds an irradiated tumor is identified. Also provided are targeting ligands that bind an irradiated tumor and therapeutic and diagnostic methods that employ the disclosed targeting ligands.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: October 2, 2018
    Assignee: WASHINGTON UNIVERSITY
    Inventors: Dennis E. Hallahan, Shimian Qu, Zhaozhong Han
  • Patent number: 10080774
    Abstract: The present invention involves compositions and methods for treating cancer using a mutant adenovirus comprising a polynucleotide encoding a therapeutic polypeptide that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming cells with a wild type retinoblastoma pathway.
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: September 25, 2018
    Assignee: Board of Regents, The University of Texas System
    Inventors: Juan Fueyo, Candelaria Gomez-Manzano, W. K. Alfred Yung, Charles A. Conrad, Frederick F. Lang, Jr.
  • Patent number: 10059747
    Abstract: The present invention provides a viral vector or bacterial vector, said vector comprising a nucleic acid sequence encoding a Crimean-Congo Haemorrhagic Fever Virus (CCHFV) glycoprotein or antigenic fragment thereof; wherein said vector is capable of inducing an immune response in a subject. The present invention also provides compositions and uses of the vector in methods of medical treatment.
    Type: Grant
    Filed: November 29, 2013
    Date of Patent: August 28, 2018
    Assignee: THE SECRETARY OF STATE FOR HEALTH
    Inventors: Karen Buttigieg, Mile Carroll, Roger Hewson, Stuart Dowall, Stephen Findlay-Wilson, Aleksandra Miloszewska
  • Patent number: 10053672
    Abstract: The present invention relates to a method for obtaining an untransformed avian cell line enabling in vitro avian virus replication. Said method includes the following steps: a) culturing avian embryonic stem cells in the presence of a stroma for at least 3 days; b) culturing for at least 2 days in a medium having a low serum concentration; c) culturing for at least 2 days in a medium having a low serum concentration containing 1 to 10 mM of hexamethyleme bisacetamide (HMBA); d) culturing for at least 10 days in a medium having a low serum concentration; and e) culturing or freezing an avian cell line enabling avian virus replication. The invention also relates to the resulting cell line and to the use thereof in vaccine preparations.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: August 21, 2018
    Assignee: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE
    Inventors: Jean-François Vautherot, Bertrand Pain, Caroline Denesvre, Laetitia Fragnet-Trapp
  • Patent number: 10046293
    Abstract: Provided herein are methods and devices for performing in situ patterned chemistry for synthesizing and preparing peptide arrays. The invention provides a reproducible and scalable platform that can be potentially used to monitor the health of a plurality of individuals.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: August 14, 2018
    Assignee: ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA
    Inventors: Neal Woodbury, Stephen Albert Johnston
  • Patent number: 9988645
    Abstract: The present invention relates nucleic acid constructs for the production of recombinant parvoviral (e.g. adeno-associated viral) vectors in insect cells, to insect cells comprising such constructs and to methods wherein the cells are used to produce recombinant parvoviral virions. The insect cells preferably comprise a first nucleotide sequence encoding the parvoviral rep proteins whereby the initiation codon for translation of the parvoviral Rep78 protein is a suboptimal initiation codon that effects partial exon skipping upon expression in insect cells. The insect cell further comprises a second nucleotide sequence comprising at least one parvoviral (AA V) inverted terminal repeat (ITR) nucleotide sequence and a third nucleotide sequence comprising a sequences coding for the parvoviral capsid proteins.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: June 5, 2018
    Assignee: uniQure IP B.V.
    Inventors: Wilhelmus Theodorus Johannes Maria Christiaan Hermens, Saskia Jacoba Petronella Haast, Dennis Johan Biesmans, Andrew Christian Bakker
  • Patent number: 9982276
    Abstract: The present invention describes generation and the use of adenovirus variants (Ad) possessing modified capsid penton base protein where mutations in the penton based RGD loop are made to avoid Ad binding to cellular ?3-integrins. Specifically, the ablation of Ad penton base interaction with cellular ?3-integrins results in reduced activation of inflammation after intravenous Ad administration. Further, the introduction into penton RGD loop of non-RGD containing peptides, which mediate virus entry into the cell via new cellular receptors, allows for the efficient Ad-mediated gene delivery into target cells in vivo after intravascular virus administration and triggers significantly reduced toxicity associated with Ad injection.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: May 29, 2018
    Assignee: ADCURE BIOTECHNOLOGIES, LLC.
    Inventors: Dmitry M. Shayakhmetov, Nelson C. Di Paolo
  • Patent number: 9951317
    Abstract: This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: April 24, 2018
    Assignee: NOVAVAX, INC.
    Inventors: Gale Smith, Yingyun Wu, Michael J. Massare, Peter M. Pushko, Margaret Nathan, Thomas Kort, Robin Robinson
  • Patent number: 9944968
    Abstract: The present invention pertains to a cell culture medium comprising media supplements that are shown to control recombinant protein glycosylation and/or cell culture in a controlled or modulated (shifted) temperature to control recombinant protein glycosylation and/or cell culture with controlled or modulated seed density to control recombinant protein glycosylation, and methods of using thereof. The present invention further pertains to a method of controlling or manipulating glycosylation of a recombinant protein of interest in a large scale cell culture.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: April 17, 2018
    Assignees: Biogen MA Inc., Samsung Bioepis
    Inventors: William Yang, Yao-Ming Huang, Kyle McElearney, Lia Tescione, James Lambropoulos, An Zhang, Valerie Tsang, Thomas Ryll, Sangil Lee, Dae Sung Lee
  • Patent number: 9926610
    Abstract: A gold nanoparticle-based colorimetric assay kit for nucleic acids from viral, bacterial and other microorganisms that detects unamplified or amplified polynucleotides in clinical specimens using unmodified AuNPs and oligotargeter polynucleotides that bind to a pathogen's nucleic acids. A method for detecting a pathogen comprising contacting a sample suspected of containing microbes with a polynucleotide that binds to pathogen nucleic acid and with gold nanoparticles, detecting the aggregation of nanoparticles, and detecting pathogen polynucleotides in the sample when the nanoparticles aggregate (solution color becomes blue) in comparison with a control or a negative sample not containing the virus when nanoparticles do not aggregate (solution color remains red).
    Type: Grant
    Filed: June 2, 2014
    Date of Patent: March 27, 2018
    Assignee: AMERICAN UNIVERSITY IN CAIRO
    Inventors: Hassan Mohamed El-Said Azzazy, Tamer Mohamed Samir, Sherif Mohamed Shawky
  • Patent number: 9890362
    Abstract: Embodiments herein report methods, compositions and uses for inducing and/or accelerating viral growth. In certain embodiments, methods, compositions and uses generally relate to copolymer compositions for inducing viral growth, reducing lag time and/or increasing viral plaque size. In other embodiments, methods, compositions and uses of copolymer compositions can be for inducing flaviviral growth, reducing lag in growth and/or increasing plaque size.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: February 13, 2018
    Assignee: Takeda Vaccines, Inc.
    Inventors: Dan T Stinchcomb, Jill A. Livengood, O'Neil Wiggan, Richard Kinney, Jorge Osorio
  • Patent number: 9890390
    Abstract: The subject invention relates in part to the surprising discovery that Cry1Da is active against corn earworm (CEW), Helicoverpa zea (Boddie). Methods for using Cry1Da in transgenic plants to prevent serious crop damage is described. Leaf and silk bioassays using transgenic maize expressing full length, core toxin region or chimeric Cry1Da demonstrated good insect protection against CEW larvae damage.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: February 13, 2018
    Assignee: Agrigenetics, Inc.
    Inventors: Sek Yee Tan, Joel J. Sheets, Todd Glancy, Aaron T. Woosley, Sarah E Worden, Diaa Alabed, Stephanie Burton, Karen C. McLaughlin, Kenneth E. Narva, Thomas Meade
  • Patent number: 9884107
    Abstract: The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (VLPs) which are useful in the treatment and prevention of Respiratory Syncytial Virus (RSV) infections and related disorders, including bronchiolitis and viral pneumonia. Related compositions (e.g. vaccines), nucleic acid constructs, and therapeutic methods are also provided. VLPs and related compositions of the invention induce high titer antibody responses against RSV. VLPs, VLP-containing compositions, and therapeutic methods of the invention induce an immunogenic response against RSV infection, confer immunity against RSV infection, protect against RSV infection, and reduce the likelihood of infection by RSV infection.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: February 6, 2018
    Assignee: STC.UNM
    Inventors: Bryce C. Chackerian, David S. Peabody
  • Patent number: 9855336
    Abstract: The present invention is drawn to liquid stable swine vaccines that comprise a live porcine virus. The invention is also drawn to the manufacture of such vaccines and methods of vaccinating animal subjects with these vaccines.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: January 2, 2018
    Assignee: Intervet Inc.
    Inventors: Kevin O'Connell, Zhisong Qiao, Brad Eddy, Erin Strait
  • Patent number: 9850513
    Abstract: The invention relates to a method for producing a recombinant protein in cells with a cell wall, comprising the step of increasing the secretion of the recombinant protein through the cell wall by expression of the protein in the cells in a culture medium containing a combination of a surface-active polymer and monovalent metal ions and with an osmolarity at least 0.32 osmol/L, said invention further relating to culture media and nutrient mixtures for the method.
    Type: Grant
    Filed: April 17, 2013
    Date of Patent: December 26, 2017
    Assignee: GREENOVATION BIOTECH GMBH
    Inventors: Wolfgang Jost, Mathias Knappenberger, Doreen Claussnitzer, Andreas Schaaf
  • Patent number: 9827305
    Abstract: The present invention is drawn to liquid stable poultry vaccines that comprise avian virus. The invention is also drawn to the manufacture of such vaccines methods of vaccinating animal subjects with these vaccines.
    Type: Grant
    Filed: February 16, 2015
    Date of Patent: November 28, 2017
    Assignee: Intervet Inc.
    Inventors: Zhisong Qiao, Stephanie Cook, Kevin O'Connell, Ian Tarpey
  • Patent number: 9816074
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a hematopoietic stem cell.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: November 14, 2017
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Anthony Conway, Gregory J. Cost, Philip D. Gregory
  • Patent number: 9796987
    Abstract: An integration-defective retroviral vector transfer cassette lacking a functional polypurine tract (PPT) is provided. Also provided are isolated nucleic acids that include a heterologous nucleotide sequence, one or two retroviral long terminal repeats (LTRs), a packaging signal, a rev responsive element, and a eukaryotic promoter, wherein the nucleic acid lacks a functional PPT; vectors that include the disclosed isolated nucleic acids; recombinant retroviral particles and mRNAs thereof; retroviral vector kits; and methods for producing integration-defective vector particles, achieving gene expression of a nucleotide sequence of interest, and inserting a nucleotide sequence of interest into a host cell genome in a site-specific or non-specific manner.
    Type: Grant
    Filed: December 11, 2008
    Date of Patent: October 24, 2017
    Assignee: The University of North Carolina at Chapel Hill
    Inventor: Tal Kafri
  • Patent number: 9765139
    Abstract: Production of etanercept using perfusion methods achieves attractive yields of properly folded protein. Desired temperature, feed media, titers and percent correctly folded protein are disclosed.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: September 19, 2017
    Assignee: Coherus Biosciences, Inc.
    Inventors: Ela Puchacz, James Russell Grove
  • Patent number: 9738690
    Abstract: The present invention relates to the field of vaccination or immunization, in particular therapeutic vaccination, and diagnosis. Pharmaceutical compositions and kits capable of eliciting a protective immune response against polyoma virus JC (JCV) are disclosed, which may be used e.g., for therapy or for prevention of progressive multifocal leukoencephalopathy (PML) and/or progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome (PML-IRIS). Individuals in danger of such PML or PML-IRIS may, e.g., be immuno-compromised or immunosuppressed patients or patients having an autoimmune disease eligible for immunosuppressive treatment. The invention also relates to compositions comprising at least one CD4+ epitope of a JCV protein and to therapeutic, prophylactic and diagnostic uses thereof.
    Type: Grant
    Filed: July 23, 2012
    Date of Patent: August 22, 2017
    Assignee: UNIVERSITAET ZUERICH
    Inventors: Ilijas Jelcic, Roland Martin, Sven Schippling, Mireia Sospedra, Sara Yousef
  • Patent number: 9732144
    Abstract: Provided herein are methods and compositions relating to Infectious Bursal Disease Virus (IBDV), and vaccines for treatment and prevention thereof.
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: August 15, 2017
    Assignee: Ohio State Innovation Foundation
    Inventor: Daral John Jackwood
  • Patent number: 9724404
    Abstract: The invention relates to modified HPV particles that can be used therapeutically. Modified HPV particles may be used to deliver therapeutic agents, including siRNA molecules. Modified HPV particles may be used for the treatment of diseases or conditions of mucosal tissue, including HPV (human papilloma virus) infection and HPV-related tumors.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: August 8, 2017
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Aura Biosciences, Inc.
    Inventors: Pierre L. Coursaget, Antoine A. Touzé, Maxime J. J. Fleury, Nicolas Combelas, Elisabet de los Pinos
  • Patent number: 9713639
    Abstract: The present invention encompasses porcine epidemic diarrhea virus (PEDV) vaccines or compositions. The vaccine or composition may be a vaccine or composition containing PEDV antigens. The invention also encompasses recombinant vectors encoding and expressing PEDV antigens, epitopes or immunogens which can be used to protect porcine animals against PEDV.
    Type: Grant
    Filed: May 19, 2015
    Date of Patent: July 25, 2017
    Assignee: MERIAL, INC.
    Inventors: Paulraj Lawrence, Russell Bey
  • Patent number: 9714435
    Abstract: The present invention provides recombinant adenoviral vectors, immunogenic compositions thereof and their use in medicine, and methods for generating recombinant adenoviral vectors. In particular, the present invention provides an adenovirus vector comprising a capsid derived from chimpanzee adenovirus AdY25, wherein said capsid encapsidates a nucleic acid molecule comprising an exogeneous nucleotide sequence of interest.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: July 25, 2017
    Assignee: OXFORD UNIVERSITY INNOVATION LIMITED
    Inventors: Matthew Douglas James Dicks, Matthew Guy Cottingham, Adrian Vivian Sinton Hill, Sarah Gilbert
  • Patent number: 9708627
    Abstract: The present invention relates nucleic acid constructs for the production of recombinant parvoviral (e.g. adeno-associated viral) vectors in insect cells, to insect cells comprising such constructs and to methods wherein the cells are used to produce recombinant parvoviral virions. The insect cells preferably comprise a first nucleotide sequence encoding the parvoviral rep proteins whereby the initiation codon for translation of the parvoviral Rep78 protein is a suboptimal initiation codon that effects partial exon skipping upon expression in insect cells. The insect cell further comprises a second nucleotide sequence comprising at least one parvoviral (AAV) inverted terminal repeat (ITR) nucleotide sequence and a third nucleotide sequence comprising a sequences coding for the parvoviral capsid proteins.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: July 18, 2017
    Assignee: UNIQURE IP B.V.
    Inventors: Wilhelmus Theodorus Johannes Maria Christiaan Hermens, Saskia Jacoba Petronella Haast, Dennis Johan Biesmans, Andrew Christian Bakker
  • Patent number: 9701945
    Abstract: The present invention relates to the development and manufacturing of viral vaccines. In particular, the invention relates to the field of industrial production of viral vectors and vaccines, more in particular to the use of avian embryonic stem cells, preferably the EBx® cell line derived from chicken embryonic stem cells, for the production of viral vectors and viruses. The invention is particularly useful for the industrial production of viral vaccines to prevent viral infection of humans and animals.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: July 11, 2017
    Assignee: Valneva
    Inventors: Majid Mehtali, Patrick Champion-Arnaud, Arnaud Leon
  • Patent number: 9694066
    Abstract: The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: July 4, 2017
    Assignee: NOVAVAX, INC.
    Inventors: Gale Smith, Rick Bright, Peter M. Pushko, Jinyou Zhang, Kutub Mahmood
  • Patent number: 9663766
    Abstract: Methods of purifying an adenovirus from an impure preparation are provided. In some embodiments, a combination of mixed mode chromatography and anion exchange chromatography is used to purify the adenovirus.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: May 30, 2017
    Assignee: Bio-Rad Laboratories, Inc.
    Inventor: Mark Irwin Fitchmun
  • Patent number: 9650682
    Abstract: Briefly described, embodiments of the present disclosure relate to methods and systems for identifying and classifying taxa of organohalide-respiring bacteria, including methods and systems for identify and classify two or more taxa of Dehalococcoides.
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: May 16, 2017
    Inventors: Alfred M. Spormann, Ian Philip George Marshall
  • Patent number: 9650612
    Abstract: Described herein is a chemostat-like continuous cell culture system that combines certain advantages of perfusion open systems and chemostat open systems to improve the culturing of mammalian cells, e.g., genetically modified cells, particularly in serum-free or chemically-defined media. The continuous culture system described herein involves culturing mammalian cells in a continuous cell culture system, which comprises a cell retention device, wherein the cell culture system has a dilution rate (D) of less than about 2 d?1, and a cell density of less than about 2×107 cell/mL.
    Type: Grant
    Filed: October 10, 2013
    Date of Patent: May 16, 2017
    Assignees: Baxalta GmbH, Baxalta Incorporated
    Inventors: Leopold Grillberger, Manfred Reiter, Daniel Fleischanderl